The supplement industry has not done enough to aid FDA in pursuing firms adulterating products with drugs or getting the message out about adulteration, the agency says. Increased vigilance is needed especially as bad actors become more sophisticated and expand their adulteration activities.
The dietary supplement industry must do more to weed out rogue businesses marketing adulterated products that threaten public health, FDA officials say.
Increased self-policing is needed especially as firms flouting supplement regulations become more sophisticated and expand their adulteration activities into new areas, agency officials and industry stakeholders said
Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.
A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.
New CBER Director Prasad will "unleash a massive" framework on vaccines, FDA Commissioner Marty Makary said 15 May, raising questions about the impact on products nearing approval.
At a House subcommittee hearing, HHS Secretary Robert F. Kennedy Jr. rebutted lawmaker concerns that NIH cuts will drive research and scientists to other countries and said he does not want to advise parents on vaccinating children for measles, chickenpox or polio.
With an FDA review ongoing, Kennedy’s admission, made during a Senate hearing on the Health and Human Services Department’s budget request, suggests political officials could supersede scientific decisions.
At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
